Medtronic (NYSE:MDT) Stock Price Expected to Rise, Barclays Analyst Says

Medtronic (NYSE:MDT) had its price objective raised by investment analysts at Barclays from $118.00 to $120.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical technology company’s stock. Barclays‘s price objective points to a potential upside of 38.56% from the company’s previous close.

Several other research analysts have also recently weighed in on MDT. Piper Sandler reduced their price objective on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Finally, Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $109.85.

Medtronic Trading Up 0.6%

Shares of NYSE:MDT opened at $86.61 on Wednesday. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company’s fifty day simple moving average is $94.76 and its 200 day simple moving average is $96.27. The firm has a market cap of $111.19 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.22 and a beta of 0.75.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic will post 5.46 EPS for the current fiscal year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medtronic

Institutional investors have recently added to or reduced their stakes in the company. Purpose Unlimited Inc. bought a new position in Medtronic during the fourth quarter worth about $8,182,000. Rockefeller Capital Management L.P. raised its stake in Medtronic by 19.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 719,949 shares of the medical technology company’s stock valued at $69,159,000 after buying an additional 118,110 shares during the period. World Investment Advisors raised its stake in Medtronic by 5.7% in the fourth quarter. World Investment Advisors now owns 167,403 shares of the medical technology company’s stock valued at $16,081,000 after buying an additional 8,961 shares during the period. Winthrop Partners WNY LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at approximately $1,223,000. Finally, Meadowbrook Advisors Group LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at approximately $2,156,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).